Management

Anat Cohen-Dayag, Ph.D.

President and CEO

Dr. Cohen-Dayag joined Compugen in 2002, and has held the positions of Director of Diagnostics, VP Diagnostic Biomarkers & Drug Targets and VP R&D. In 2009, Dr. Cohen-Dayag was appointed, together with Mr. Martin Gerstel, as co-CEO of Compugen. In 2010, Dr. Cohen-Dayag was appointed Compugen President and CEO. Prior to joining Compugen, she was head of R&D and a member of the executive management at Mindsense Biosystems. Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in chemical immunology and a Ph.D. in cellular biology from the Weizmann Institute of Science. In addition, Dr. Cohen-Dayag is a director of Ramot at Tel Aviv University Ltd., and a director of the IATI (Israeli Advanced Technologies Industries).

Ari Krashin

Chief Financial and Operating Officer

Mr. Krashin joined Compugen in 2014 as Chief Financial Officer of Compugen. In 2016, he was appointed also Chief Operating Officer. Mr. Krashin has over 15 years of experience in capital markets, finance and business development. He served as a chief financial officer for both public and private companies, the most recent being AnyClip Media and Spacenet Inc. Mr. Krashin was also the CFO of Gilat Satellite Networks where he led the company's global finance and related operations, including business development, M&A activities, investor relations and administration. Mr. Krashin is a certified public accountant and began his professional career with Kesselman and Kesselman, PWC, Israel. Mr. Krashin holds a B.A. in Business Administration and Accounting from the College of Management, Rishon Le’Zion.

Zurit Levine, Ph.D.

Vice President, Research & Discovery

Dr. Levine joined Compugen in 1999 and has held the positions of director of therapeutic selection and validation, director of therapeutic discovery, and executive director of R&D. Dr. Levine holds a B.Sc. in Biology from Tel Aviv University, Israel, and an M.Sc. and Ph.D. in Biochemistry, both from Tel Aviv University, Israel.

John Hunter, Ph.D.

Vice President, Antibody R&D and Site Head, Compugen USA, Inc.

Dr. Hunter brings to Compugen USA, Inc. over 15 years of scientific expertise in mAb research, genomics and translational medicine. As Vice President Antibody Research and Development and Compugen USA, Inc. Site Head, he leads the generation and preclinical development of mAb therapeutics against Compugen-discovered targets. Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to building a robust preclinical mAb pipeline. He began his industry career at Millenium Pharmaceuticals, where he specialized in oncology therapeutics research.

Tsipi Keren-Lehrer

Vice President, Business Development

Ms. Keren-Lehrer was appointed VP BD in 2013. She joined Compugen's R&D in 2001 as an Application Engineer, and later was responsible for the Company's research grants in her role as Research Grant Manager. Ms. Keren-Lehrer joined Compugen's Business Development Unit in 2007, and at the beginning of 2012 she took the position of Head of the business development activities and joined the company management. Ms. Keren-Lehrer holds a B.Sc. in Biology and an LL.B. both from Tel Aviv University, and she is a certified lawyer in Israel.

Dorit Amitay

Vice President, Human Resources

Dorit Amitay joined the human resources department at Compugen in 1999, bringing with her over ten years of experience. During her tenure at the Company, she took on increasingly larger roles in the HR department until assuming her current position in 2007. Prior to joining Compugen, Ms. Amitay worked for one of leading Israeli recruitment and placement agencies. She holds a B.A. and an M.B.A., both from Ben Gurion University in Israel.

Leadership Compugen USA Inc.

John Hunter, Ph.D.

Vice President, Antibody R&D and Site Head, Compugen USA, Inc.

Dr. Hunter brings to Compugen USA, Inc. over 15 years of scientific expertise in mAb research, genomics and translational medicine. As Vice President Antibody Research and Development and Compugen USA, Inc. Site Head, he leads the generation and preclinical development of mAb therapeutics against Compugen-discovered targets. Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to building a robust preclinical mAb pipeline. He began his industry career at Millenium Pharmaceuticals, where he specialized in oncology therapeutics research.

Drew Pardoll, M.D., Ph.D.

Director, Compugen USA, Inc.

Prof. Drew Pardoll, the Chairman of Compugen’s Scientific Advisory Board, is the Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center, Johns Hopkins. For the past two decades, Prof. Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system and has made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy, and his research led the clinical development of the first anti-PD-1 antibody. Prof. Pardoll is the inventor of a number of immunotherapies, including cancer vaccines, and was a scientific founder of Amplimmune Inc. Prof. Pardoll completed his M.D., Ph.D, Medical Residency and Oncology Fellowship at Johns Hopkins University.

Richard T. Haiduck

Director, Compugen USA, Inc.

Mr. Haiduck has more than 30 years of extensive general management experience with prominent life sciences companies, across a broad range of technologies. He has successfully built companies, led and participated in private and public financings, and has done significant strategic alliances with the majority of big pharma companies. He has had over 20 strategic consulting relationships with leading public and private life sciences companies. He was Managing Director in the Merchant Banking Group at Burrill & Company. He has held 6 CEO or Managing Director roles for BioStreet, Desmos, LifeScreen and multiple US and international operations of Abbott Laboratories. He was VP of Corporate Development at Geron. Mr. Haiduck has his undergraduate degree in Marketing from Miami University, Oxford, Ohio and his MBA in Finance from Xavier University, Cincinnati, Ohio